Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms.
The final diagnosis of BPDCN relies on a compatible immunophenotype. The triple-positive CD4+CD56+CD123+ phenotype associated with negativity for lineage-specific markers is a minimum requirement for defining BPDCN. The highly specific marker BDCA2/CD303, as well as other plasmacytoid dendritic cell-associated antigens (e.g. TCL1 and CD2AP), might be of great support to exclude potential mimickers of BPDCN (acute myeloid and monocytic leukemias, precursor lymphoblastic T-cell leukemia/lymphomas and T- and NK/T cell lymphomas).
At present, there is no consensus on the optimal treatment of BPDCN. The majority of patients receive multi-agent chemotherapy with AML or ALL treatment regimens, while a few patients undergo allogeneic hematopoietic stem cell transplantation (HSCT). Different novel and innovative therapies are in development to target surface molecules in BPDCN. However, patients are still in need of better treatments and the optimal therapy for the disease remains to be determined.
Through this project, we aim to build a large database of patients with BPDCN to investigate the characteristics and outcomes of the disease with different treatment regimens, evaluate prognostic factors, and generate data-based prospective treatment recommendations.
This is a multicenter, international prospective, and retrospective registry. Patients of all sexes and ages who have a diagnosis of BPDCN are eligible for enrolment. Prospective patients must provide informed consent to be eligible to participate. Patients will be recruited directly by national study groups and participating centers.
Prospective participants will be recruited through June 2027. Each participant will be followed-up for 5 years. Retrospective data of patients diagnosed with BPDCN since January 2010 will also be collected.
Principle Investigator:
Astghik Voskanyan, MD
Immune Oncology Research Institute, Yerevan, Armenia
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
[email protected], [email protected]
Advisors:
Naveen Pemmaraju, MD
MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX 77030, USA
E-mail: [email protected]
Marina Konopleva, MD, PhD
Blood Cancer Institute, Montefiore Einstein, 1575 Blondell Ave, Bronx, NY 10461, United States
E-mail: [email protected]
Registry coordinator:
Karen Bedirian, MPH
Immune Oncology Research Institute, Yerevan, Armenia
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
[email protected]
Co-investigators:
Gevorg Tamamyan, MD, MSc, Ph.D., DSc
Immune Oncology Research Institute, Yerevan, Armenia
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Yerevan State Medical University, Yerevan, Armenia
[email protected], [email protected]
Maria Badikyan, MD
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
[email protected]
Nare Martirosyan, MD
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
[email protected]
Ruzanna Papyan, MD
Immune Oncology Research Institute, Yerevan, Armenia
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Yerevan State Medical University, Yerevan, Armenia
[email protected]
Lida Melikyan, MD
Wigmore Women's & Children's hospital, 10a Nersisyan St, Yerevan 0014, Armenia
[email protected]
Shushan Hovsepyan, MD
Yeolyan Hematology and Oncology Center
Immune Oncology Research Institute
[email protected]
Clodet Stepanian, MD
Yeolyan Hematology and Oncology Center
[email protected]
Narine Ghazaryan, PhD
Yeolyan Hematology and Oncology Center
[email protected]
Alvard Poghosyan, MD
Yeolyan Hematology and Oncology Center
[email protected]
Nerses Ghahramanyan, MD
Yeolyan Hematology and Oncology Center
[email protected]
Biometrics:
Arusyak Ivanyan, MD
Yeolyan Hematology and Oncology Center
E-mail: [email protected]
Biobank:
Narine Ghazaryan, PhD
Yeolyan Hematology and Oncology Center
E-mail: [email protected]
Pediatric:
Shushan Hovsepyan, MD
Yeolyan Hematology and Oncology Center
Immune Oncology Research Institute
[email protected]
Statistical office:
Arusyak Ivanyan, MD
Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
Sponsor:
Immune Oncology Research Institute
Participating centers:
Armenia
Hematology Center named after Prof. R. Yeolyan, Yerevan, Armenia
Investigators:
Astghik Voskanyan, MD - [email protected], [email protected]
Gevorg Tamamyan, MD, PhD, DSc - [email protected]
United States
1. Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, US
Investigators:
Dickran Kazandjian, MD - [email protected]
Alvaro Alencar, MD - [email protected]
2. Seattle Children’s Cancer and Blood Disorders Center, Seattle, Washington, USA
Investigators:
Adam Lamble, MD
[email protected]
Egypt
Oncology Center, Mansoura University Faculty of Medicine, Mansoura, Egypt
Investigators:
Shaimaa El-Ashwah, MD - [email protected]
Georgia
M. Iashvili Children's Central Hospital, Tbilisi, Georgia, 0159
Investigators:
Nino Totogashvili, MD - [email protected]
United Kingdom
Broomfield Hospital, Haematology Mid, and South Essex University Hospitals Group, Chelmsford, Essex, United Kingdom
Investigators:
Pavel P Kotoucek, Ph.D., FRCPath - [email protected]
Cyprus
Cyprus Society of Haematology, Nicosia, Cyprus, 2019
Investigators:
Michalis Michael, MD - [email protected]
Italy
1. University of Perugia - Azienda Ospedaliera Perugia, Perugia, Italy
Investigators:
Maria Paola Martelli, MD, Ph.D. - [email protected]
2. University of Rome Tor Vergata, Department of Biomedicine and Prevention, Roma, Italy
Investigators:
Maria Teresa Voso, MD - [email protected]
Canada
1. University of Calgary, Alberta, Canada
Investigators:
Carolyn Owen, MD - [email protected]
2. Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada
Investigators:
Consolato Sergi, MD, PhD - [email protected]
India
Department of Medical Oncology, Dr B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
Investigators:
Sameer Bakhshi, MBBS, MD, DM
Iraq
Pediatric Hematology Oncology, Children’s Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad, Baghdad, Iraq
Investigators:
Mazin Faisal Al-Jadiry, MD - [email protected]
Hasanein Habeeb Ghali, MD - [email protected]
Kuwait
Department of hematology, Kuwait Cancer Control Center
Investigators:
Ahmad Alhuraiji, MD, MRCP (UK)
Taiwan
China Medical University Children’s Hospital, Taichung, Taiwan
Investigators:
Min-Yu Su, MD - [email protected]
Ching-Tien Peng, MD
Turkey
1. Turkish Pediatric Cancer Registry, Ankara, Turkey
Investigators:
Tezer Kutluk, MD, PhD - [email protected]
2. Istanbul University, Oncology Institute, Istanbul, Turkey
Investigators:
Rejin Kebudi, MD - [email protected]
3. University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit, Istanbul, Turkey
Investigators:
Funda Tekkesin, MD - [email protected]
Romania
Fundeni Clinical Institute, Department of Acute Leukemia, Bucharest, Romania, 022328
Investigators:
Maria Camelia Stancioacia, MD
Daniel Coriu, MD, PhD
More information about this study can be found at
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry - Full Text View - ClinicalTrials.gov
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.